Log In

 
Company : Ferring Pharmaceuticals 
Tuesday, January 31, 2017 2:52PM IST (9:22AM GMT)
 
(BW)(FERRING-PHARMACEUTICALS)
Ferring Pharmaceuticals and Enteris BioPharma Enter License Agreement to Develop an Oral Formulation of a Peptide-based Injectable Therapeutic
Saint-Prex, Switzerland

Ferring Pharmaceuticals and Enteris BioPharma, Inc. announced that the companies have entered into a license agreement and initiated an early development agreement to leverage Enteris’ proprietary and patented oral peptide and small molecule delivery platform, Peptelligence™, to engineer an oral formulation of a peptide-based injectable therapeutic developed by Ferring.

 

Under the terms of the agreement, Enteris BioPharma will license to Ferring its oral drug delivery technologies, as well as provide clinical trial finished product, and will receive milestones and royalties based on net sales of the developed product.

 

The licensing agreement with Ferring Pharmaceuticals highlights Enteris BioPharma’s successful “Feasibility-to-Licensing” strategy involving Peptelligence™, its peptide and small molecule oral drug delivery platform. The technology is currently the subject of several active external development programs and has proven effective over the last decade to enable the safe delivery of peptide-based therapeutics and other molecules with low oral bioavailability.

 

Joel Tune, Chief Executive Officer and Executive Chairman of Enteris BioPharma, remarked, “Our agreement with Ferring Pharmaceuticals exemplifies the opportunity our Peptelligence platform offers in enhancing the market potential of peptide-based therapeutics by enabling the oral delivery of medications that must otherwise be administered by injection. We are excited to work with an industry leader like Ferring Pharmaceuticals to advance the development of an oral peptide-based therapeutic.”

 

Alan Harris, Senior Vice President, R&D Executive Office of Ferring Pharmaceuticals, remarked, “The ability to deliver oral peptides offers Ferring the opportunity to provide additional therapeutic choices to patients. We are impressed with Enteris’ proprietary oral delivery technology and look forward to working with them to advance this development program.”

 

ENDS

 

About Ferring Pharmaceuticals

 

Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. To learn more about Ferring or its products please visit www.ferring.com.

 

About Enteris BioPharma

 

Enteris BioPharma, Inc. is a privately held, New Jersey-based biotechnology company offering innovative formulation solutions built around its proprietary drug delivery technologies. The Company’s proprietary oral delivery technology – Peptelligence™ - has been the subject of numerous feasibility studies and active development programs, several of which are in late stage clinical development. Additionally, Enteris BioPharma has built and is advancing an internal product pipeline of oral tablet reformulations of drug products that address significant treatment opportunities for which there is no oral delivery option. Enteris BioPharma’s most advanced internal product candidate, Ovarest™ (oral leuprolide tablet), is a Phase 2a-ready oral peptide, being developed for the treatment of endometriosis. For more information on Enteris BioPharma and its proprietary oral delivery technology and contract manufacturing capabilities, please visit www.enterisbiopharma.com.

 

 

 

 

 
For News Release background on Ferring Pharmaceuticals click here
 
Media Contact Details
CONTACTS : Ferring Pharmaceuticals Lindsey Rodger Tel. +41 58 451 40 23 lindsey.rodger@ferring.com or Enteris BioPharma: Brian Zietsman, President & CFO +1 973 453 3527 or Enteris Media Relations: Jason Rando / Amy Wheeler Tiberend Strategic Advisors, Inc. +1 212 827 0020 jrando@tiberend.com awheeler@tiberend.com
 
 
Submit your press release
More News from Ferring Pharmaceuticals

10/04/2017 6:15PM

Ferring Announces Exclusive Agreement with Alrise Biosystems for the Development of an Injectable, Controlled-Release Peptide

Ferring Pharmaceuticals and Alrise Biosystems announced today that the companies have entered into a development agreement with exclusive option rights for Ferring to leverage Alrise’s ImSus® Technology ...

07/04/2017 10:10AM

Ferring Highlights Progress on Social and Environmental Goals in Corporate Social Responsibility (CSR) Review 2015-2016

Ferring Pharmaceuticals releases its second Corporate Social Responsibility (CSR) review, highlighting progress on social and environmental goals in 2015 and 2016 across four key pillars for focus and activity: People, ...

03/04/2017 8:10PM

Ferring Appoints Dominic Moorhead as Executive Vice President and Chief Financial Officer

Ferring Pharmaceuticals announced today that Dominic Moorhead has been appointed as Executive Vice President and Chief Financial Officer, effective 1st July 2017.   Moorhead succeeds Peter Wilden, who joined ...

Similar News

27/04/2017 11:10PM

MATRIXX Software Launches Carrier-Grade Digital Commerce Platform For Cloud

MATRIXX Software (http://www.matrixx.com/) today announced the launch of MATRIXX Digital Commerce, a single platform that delivers the same carrier-grade performance and reliability Communications Service Providers ...

No Image

27/04/2017 10:50PM

Bertin’s Second Sight® MS Standoff Gas-Detection Camera Chosen by the Australian Army

Bertin Technologies, a subsidiary of CNIM, has announced that its Second Sight® MS standoff detector of chemical threats has just been chosen by the Australian Defence Force (ADF) to equip its troops.   This ...